Complement C1s

Complement C1s Molekülinformation

Englischer Name	Complement C1s	Anzahl der inverkehr gebrachten Arzneimittel	4
Anzahl der klinischen Arzneimittel	5	Target-Alias	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Complement C1s
Target-Alias	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Anzahl der inverkehr gebrachten Arzneimittel	4
Anzahl der klinischen Arzneimittel	5
Höchste Forschungs- und Entwicklungsphase	Approved

Complement C1s Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (1)Cynomolgus (1)
Etikett
His Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
COS-H52H3	Human	HEK293	Human Complement C1s Protein, His Tag, low endotoxin (MALS verified)				In den Warenkorb legen
COS-C52H3	Cynomolgus	HEK293	Cynomolgus Complement C1s Protein, His Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge2

Complement C1s Molekülhintergrund

This gene encodes a serine protease, which is a major constituent of the human complement subcomponent C1. C1s associates with two other complement components C1r and C1q in order to yield the first component of the serum complement system. Defects in this gene are the cause of selective C1s deficiency.

Complement C1s Molekülalias

EDSPD2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Complement-C1 inhibitor protein (Octapharma)		Phase 3 Clinical	Octapharma	Angioedemas, Hereditary	Details
Riliprubart	BIVV-020; SAR-445088; TNT-020	Phase 3 Clinical	True North Therapeutics	Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic	Details
C1 esterase inhibitor (Boya Bio-Pharmaceutical)		Phase 3 Clinical	Boya Bio-Pharmaceutical Group Co Ltd	Angioedemas, Hereditary	Details
Claseprubart	DNTH103; DNTH-103	Phase 3 Clinical	Dianthus Therapeutics Inc	Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Details
C1 esterase inhibitor (Chengdu Institute of Biological Products)		Phase 1 Clinical	Chengdu Institute Of Biological Products Co Ltd	Angioedemas, Hereditary	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Conestat alfa	rhC1-INH	Approved	Pharming Group Nv	Rhucin, Esterasine, Ruconest	EU	Angioedemas, Hereditary	Pharming Group Nv	2010-10-28	Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency	Details
Sutimlimab	BIVV-009; TNT-009	Approved	True North Therapeutics	ENJAYMO	United States	Anemia, Hemolytic, Autoimmune	Recordati Rare Diseases Inc	2022-02-04	Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic	Details
Complement C1 inhibitor protein (Shire ViroPharma)	C1 INH-nf; C1-INH; SHP-616	Approved	Sanquin Plasma Products Bv	Cinryze, Cetor	United States	Angioedemas, Hereditary	null	2008-10-10	Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation	Details
C1 esterase inhibitor (Human, CSL Behring)	BI-3.012; CSL-830; CSL-842; CE-1145	Approved	Csl Behring Llc	Berinert, Haegarda, Berinert 2000	Japan	Angioedemas, Hereditary	Csl Behring Llc	1990-06-29	Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation	Details